"Combined Fist" cracks the new auxiliary treatment of rectal cancer

Is there a more optimized treatment "combination fist" based on the new complementary treatment of "chemotherapy and radiotherapy" for a period of time before surgery in patients with local progressive rectal cancer who are unable to perform surgery immediately, which can improve the surgical excision rate and long-term survival benefits of this group of patients?
In response to this treatment "difficult situation" that has plagued the industry for many years, a multidisciplinary comprehensive diagnosis and treatment team for colorectal cancer at Fudan University-affiliated Oncology Hospital took 2 years to provide an answer to an original study completed by 17 hospitals across the country. The study was published October 30 in the Journal of Clinical Oncology.Cai Sanjun (first from right) carefully formulated a diagnosis and treatment plan for patients at the multidisciplinary clinic for colorectal cancer." early rectal cancer surgery, the patient's five-year survival rate can reach 90%, equivalent to clinical cure. However, about 80% of outpatient first-time patients found in the clinic is already in the middle or even late stage, some local progression of bowel cancer patients due to larger lesions or closer to the anus, it is difficult to immediately carry out surgical excision, 5-year survival rate has been hovering around 70%. "Professor Cai Sanjun, lead expert of the multidisciplinary comprehensive diagnosis and treatment team of colorectal cancer at Fudan University's affiliated oncology hospital.
for these patients with localized progressive rectal cancer, the surgical pathology showed a complete remission rate of 8% in 2004 in the New England Journal of Medicine, standard treatment for new assisted radiotherapy and surgery for rectal cancer.
in this treatment mode, about one-third of patients experience distant metastasis, leading to treatment failure. To this end, Fudan University affiliated oncology hospital radiotherapy professor Zhang Really, Zhu Wei has been concerned about this "difficult situation." Since 2012, they have been exploring the use of the traditional drug Iliticon for new complementary radiotherapy for rectal cancer. Through systematic literature review, the team selected UGT1A1 as the dose-guided gene of Ilithikang, and laid the foundation for the previous research through continuous dose climbing research and platform period expansion research.Zhangxuan (first from left) led colleagues to conduct a symposium on scientific research.Since December 2015, Fudan Cancer Hospital, in partnership with 17 hospitals across the country, has randomly divided 360 patients aged 24 to 75 years from the anus ≤10cm from the tumor lesions, and phased T3/T4 patients with or without lymph node-positive stage II/III rectal cancer, randomly divided into "Kapetabin and Iliticon co-captains". The treatment group (the following: study group) and the treatment group of "Kapetabin single drug combined long-range radiotherapy" (the following: control group), waited 8 weeks after 5 weeks of radiotherapy for root treatment (period increased interval chemotherapy), the results showed that compared with the control group, the probability of tumor disappearance (CR) in the study group showed double the positive results compared to the control group.
Zhu said that for patients with local progressive rectal cancer, our clinical trial program is tightly riveted "gene esotype", that is, the most talked about "tumor precision treatment".
understand that before entering the group of this study, each patient must first carry out the relevant gene bit testing. Relevant studies have confirmed that UGT1A1 wild and hybrid mutant bowel cancer patients have significantly increased dose tolerance to Eriticon drugs compared to patients with pure mutations. Therefore, only patients with bowel cancer with wild or hybrid mutants with gene expression can be included in the group, while patients with pure mutants are less resistant to elitricon drugs and prone to serious adverse reactions, so they are considered unsuitable for such treatment models and are not included in the study population.
"Although we added a chemotherapy drug called iliticon to the study group's program, the toxicity of patients increased significantly, we found that the patient's condition was clinically controllable. Zhang said.
In addition, the team also found in a retrospective analysis that the rate of disease relief was only 20% in patients with insufficient weekly dose application and 1 to 3 medications for various reasons, while the rate of disease relief was only 20%, while the rate of disease relief was only 20%;
" We recommend that in the future clinical process to obtain a more satisfactory tumor withdrawal effect, in the new auxiliary chemotherapy process should be as far as possible to allow patients to use iliticocon to reach the weekly dose standard and the number of times the use of drugs reached 4 times and above. Zhang said.Zhu Wei (second from right) receives each patient carefully at the clinic.fact, new complementary treatments for bowel cancer have developed rapidly in the last decade. From the 8% pathological complete remission rate of post-physiotherapy surgery in the CAO/ARO/AIO-94 study in Germany, to the CinClare study, the pathological complete remission rate has been increased to 34% after more than 10 years of continuous efforts on new complementary treatment models.
Many patients who originally lost the opportunity to operate, after the new auxiliary chemotherapy to obtain the opportunity of surgical root treatment, and more importantly, some patients with strong protection, after a period of new auxiliary radiotherapy, the lesions narrowed, reached the opportunity to protect the anus and can be surgically cured, which let us see the significant advantages and results of multidisciplinary comprehensive treatment. Zhang said.
, Zhu believes the results will maximize benefits for both groups of patients. The first category is the first treatment can not achieve satisfactory bowel cancer treatment excision patients, through this program after treatment to win the opportunity to cure excision, to achieve better long-term survival benefits, the second category is the first diagnosis can not protect the anus, such as strong protection, tumor load of low rectal cancer patients, can be given an retention opportunity through this treatment model.
Cai Sanjun said that cancer treatment urgently needs multidisciplinary deep integration and participation, in the surgery technology reached the limit, we need to use a combination of treatment methods to provide new strategies and possibilities for protection, so that more patients with bowel cancer not only access to protection opportunities, but also long-term survival rate. (Photo provided by Fudan Cancer Hospital) (Source: Zhang Sihui, China Science Daily)
relevant paper information: